title: Safety and efficacy of a combination therapy with Revlimid, Adriamycin and dexamethasone (RAD) in relapsed/refractory multiple myeloma (MM): a single-centre experience.
authors.forename: Tommaso
authors.initials: T
authors.lastname: Caravita
authors.forename: Agostina
authors.initials: A
authors.lastname: Siniscalchi
authors.forename: Andrea
authors.initials: A
authors.lastname: Tendas
authors.forename: Luca
authors.initials: L
authors.lastname: Cupelli
authors.forename: Micaela
authors.initials: M
authors.lastname: Ales
authors.forename: Alessio
authors.initials: A
authors.lastname: Perrotti
authors.forename: Pasquale
authors.initials: P
authors.lastname: Niscola
authors.forename: Paolo
authors.initials: P
authors.lastname: de Fabritiis
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003907:Dexamethasone / Q000008:administration & dosage* / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality; D012008:Recurrence; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D016896:Treatment Outcome
chemical_list: D013792:Thalidomide; D003907:Dexamethasone; D004317:Doxorubicin; D000077269:Lenalidomide